⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13767410 | 0.76 | — | — | |
| SCHEMBL898668 | 0.72 | — | — | |
| SCHEMBL22653550 | 0.70 | — | — | |
| SCHEMBL14655482 | 0.70 | — | — | |
| SCHEMBL23432304 | 0.70 | — | — | |
| Methyl Alcohol SCHEMBL16568700 | 0.68 | MEN1 (0.31) | — | |
| SCHEMBL18227967 | 0.67 | NOS3 (0.31) | — | |
| SCHEMBL19113688 | 0.65 | — | — | |
| SCHEMBL25369350 | 0.65 | — | — | |
| SCHEMBL1568783 | 0.65 | MEN1 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0988061-A4 | METHODS FOR DELIVERING BIOACTIVE AGENTS | IMARX PHARMACEUTICAL CORP (US) | 2002-05-02 | — | — | EP | claimed |
| US-6143276-A | ADMINISTERING TO THE PATIENT A COMPOSITION COMPRISING A BIOACTIVE AGENT AND A GASEOUS PRECURSOR CAPABLE OF UNDERGOING PHASE TRANSITION TO A GAS AT A REGION OF ELEVATED TEMPERATURE IN THE PATIENT | IMARX PHARMACEUTICAL CORP. (US) | 2000-11-07 | — | — | US | claimed |
| EP-0988061-A1 | METHODS FOR DELIVERING BIOACTIVE AGENTS | IMARX PHARMACEUTICAL CORP. (US) | 2000-03-29 | — | — | EP | claimed |
| WO-1998042384-A1 | METHODS FOR DELIVERING BIOACTIVE AGENTS | IMARX PHARMACEUTICAL CORP. (US) | 1998-10-01 | — | — | WO | claimed |
| EP-2766001-B1 | BUFFERED OXYGEN THERAPEUTIC | NUVOX PHARMA LLC (US) | 2024-05-15 | — | — | EP | disclosed |
| US-8822549-B2 | Buffered oxygen therapeutic | NUVOX PHARMA LLC | 2014-09-02 | — | — | US | disclosed |
| EP-2766001-A1 | BUFFERED OXYGEN THERAPEUTIC | Nuvox Pharma, LLC (US) | 2014-08-20 | — | — | EP | disclosed |
| US-20130096204-A1 | Buffered Oxygen Therapeutic | NUVOX PHARMA LLC | 2013-04-18 | — | — | US | disclosed |
| WO-2013056246-A1 | BUFFERED OXYGEN THERAPEUTIC | NUVOX PHARMA L.L.C. (US) | 2013-04-18 | — | — | WO | disclosed |
| EP-1015039-B1 | OXYGEN DELIVERY AGENTS AND USES FOR THE SAME | IMARX PHARMACEUTICAL CORP (US) | 2008-08-27 | — | — | EP | disclosed |
| US-20070059248-A1 | Oxygen delivery agents and uses for the same | IMARX THERAPEUTICS, INC. | 2007-03-15 | — | — | US | disclosed |
| US-7105151-B2 | Oxygen delivery agents and uses for the same | IMARX THERAPEUTICS, INC. (US) | 2006-09-12 | — | — | US | disclosed |
| EP-1015039-A1 | OXYGEN DELIVERY AGENTS AND USES FOR THE SAME | IMARX PHARMACEUTICAL CORP. (US) | 2000-07-05 | — | — | EP | disclosed |
| EP-0988061-A1 | METHODS FOR DELIVERING BIOACTIVE AGENTS | IMARX PHARMACEUTICAL CORP. (US) | 2000-03-29 | — | — | EP | disclosed |
| US-6028066-A | FOR DELIVERING HIGHER CONCENTRATIONS OF BIOACTIVE AGENTS TO IMPROVE EFFICACY OF THE BIOACTIVE AGENTS | IMARX PHARMACEUTICAL CORP. (US) | 2000-02-22 | — | — | US | disclosed |
| WO-1999030620-A1 | OPTOACOUSTIC CONTRAST AGENTS AND METHODS FOR THEIR USE | IMARX PHARMACEUTICAL CORP. (US) | 1999-06-24 | — | — | WO | disclosed |
| WO-1998057670-A1 | OXYGEN DELIVERY AGENTS AND USES FOR THE SAME | IMARX PHARMACEUTICAL CORP. (US) | 1998-12-23 | — | — | WO | disclosed |
| WO-1998050041-A1 | NOVEL PRODRUGS COMPRISING FLUORINATED AMPHIPHILES | IMARX PHARMACEUTICAL CORP. (US) | 1998-11-12 | — | — | WO | disclosed |
| WO-1998042383-A1 | CHARGED LIPIDS AND USES FOR THE SAME | IMARX PHARMACEUTICAL CORP. (US) | 1998-10-01 | — | — | WO | disclosed |
| WO-1998042384-A1 | METHODS FOR DELIVERING BIOACTIVE AGENTS | IMARX PHARMACEUTICAL CORP. (US) | 1998-10-01 | — | — | WO | disclosed |